Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma

Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma

Mounting evidence links the phenomenon of enhanced recruitment of tumor-associated macrophages towards cancer bulks to neoplastic growth, invasion, metastasis, immune escape, matrix remodeling, and therapeutic resistance. In the context of cancer progression, naïve macrophages are polarized into M1...

Full description

Bibliographic Details
Main Authors:	Huey-Jen Lin, Yingguang Liu, Kailey Caroland, Jiayuh Lin
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Cancers
Subjects:	angiogenesis chemoresistance epithelial–mesenchymal transition extracellular matrix gemcitabine hypoxia
Online Access:	https://www.mdpi.com/2072-6694/15/13/3507

Similar Items

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
by: Ella Rimmer, et al.
Published: (2022-07-01)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
by: Tadataka Takagi, et al.
Published: (2023-04-01)

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
by: Jinsheng Ding, et al.
Published: (2021-11-01)

Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence
by: Ashish Manne, et al.
Published: (2023-04-01)

Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma
by: Keisuke Okuno, et al.
Published: (2023-01-01)

RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma
by: Qiu Tu, et al.
Published: (2022-09-01)

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles
by: Chen Z, et al.
Published: (2018-01-01)

M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer
by: Yongmei Zhao, et al.
Published: (2021-09-01)

Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma
by: Keisuke Okuno, et al.
Published: (2022-09-01)

CD95L Inhibition Impacts Gemcitabine-Mediated Effects and Non-Apoptotic Signaling of TNF-α and TRAIL in Pancreatic Tumor Cells
by: Khalid Rashid, et al.
Published: (2021-10-01)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
by: Hyung Sun Kim, et al.
Published: (2021-02-01)

Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1
by: Helena Doktorova, et al.
Published: (2015-06-01)

Effect of Adenomatous Polyposis Coli Loss on Tumorigenic Potential in Pancreatic Ductal Adenocarcinoma
by: Jennifer M. Cole, et al.
Published: (2019-09-01)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
by: Annalisa Comandatore, et al.
Published: (2022-01-01)

microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer
by: Naotake Funamizu, et al.
Published: (2023-02-01)

Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01)

Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells
by: Serkan Sayin, et al.
Published: (2023-02-01)

Metabolism of pancreatic cancer: paving the way to better anticancer strategies
by: Cheng Qin, et al.
Published: (2020-03-01)

The effect of cycling hypoxia on MCF-7 cancer stem cells and the impact of their microenvironment on angiogenesis using human umbilical vein endothelial cells (HUVECs) as a model
by: Fuad M. Alhawarat, et al.
Published: (2019-01-01)

Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
by: Aleksandra Adamska, et al.
Published: (2017-06-01)

Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
by: Kostas Palamaris, et al.
Published: (2021-11-01)

Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
by: Huey-Jen Lin, et al.
Published: (2022-01-01)

Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis
by: Takashi Ando, et al.
Published: (2020-10-01)

Effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: a retrospective study
by: Yu Xun, et al.
Published: (2018-04-01)

An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
by: Tianpeng Zhang, et al.
Published: (2023-12-01)

DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines
by: Maria Urbanova, et al.
Published: (2022-02-01)

Amurensin G Sensitized Cholangiocarcinoma to the Anti-Cancer Effect of Gemcitabine via the Downregulation of Cancer Stem-like Properties
by: Yun-Jung Na, et al.
Published: (2023-12-01)

GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer
by: Chen Chen, et al.
Published: (2022-07-01)

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer
by: Mathieu Chocry, et al.
Published: (2022-11-01)

Identification of a chemoresistance-related prognostic gene signature by comprehensive analysis and experimental validation in pancreatic cancer
by: Junliang Chen, et al.
Published: (2023-05-01)

USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2
by: Jing Cui, et al.
Published: (2023-10-01)

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
by: Zhiqing Bai, et al.
Published: (2022-04-01)

Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(D,L-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival
by: Allison Logan S, et al.
Published: (2017-07-01)

Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line
by: Sara Peri, et al.
Published: (2021-07-01)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
by: Jerome Raffenne, et al.
Published: (2019-11-01)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
by: Chenqi Wang, et al.
Published: (2022-06-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma
by: Junhui Liu, et al.
Published: (2020-07-01)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
by: Victor Mortier, et al.
Published: (2022-12-01)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)